Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of intravitreal Zimura for geographic atrophy secondary to dry age-related macular degeneration
MOH_2020-06-07_009012Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Apr 2020
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of avacincaptad pegol in dry age-related macular degeneration and age-related macular degeneration (AMD) (2 arms), sponsored by Astellas Pharma. Started Apr 2020; status: completed.
02
Drugs
avacincaptad pegol
03
Conditions
dry age-related macular degenerationage-related macular degeneration (AMD)
Beyond the preview
Go deeper on MOH_2020-06-07_009012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-06-07_009012.